Kornimate/medical-research-clean huggingface dataset:
arm motor rehabilitation, entertainment and cognition system for the elderly

Conditions: Stroke

Summary: the research project is intended to provide information pertaining to the feasibility of the brightarm compact robotic rehabilitation system for patients early sub-acute post cerebral vascular accident. the aims are to: a) determine clinical benefit to motor and cognitive function as well as mood; 2) to ascertain technology acceptance by patients and therapists. the experimental training consists of 12 integrative arm/hand and cognitive training by playing therapeutic games. participants are evaluated pre-and post-intervention and provide subjective evaluation of the system.

this study targets participants, who had suffered a first stroke recently, and who may or may not have been diagnosed with mild cognitive impairments or dementia (including alzheimer's disease). it is important to find out if these improvements can be obtained with the computer game-based integrative (motor-cognitive) bilateral rehabilitation developed by bright cloud international corp, and if these gains transfer to daily activities. specific aims are: * bac technology acceptance; * improvement in motor function for the upper extremity; * strengthening of shoulder and fingers; * increased active (self initiated) range of motion for shoulder, arms and fingers; * improved independence in activities of daily living; * improvement in cognitive areas of memory, attention and decision making; * improved mood (as in reduced depression severity);

Eligibility criteria:
inclusion criteria: * age 50 to 85; * diagnosis of first-time cva that occurred more than 5 days prior and less than 21 days prior * english speakers; * ue unilateral or bilateral involvement (from new bilateral cva) * motor involvement (fma score 20 to 45); * ability to actively move ue more than 10 degrees for shoulder and elbow flexion/extension; * ability to actively extend fingers at least 5 degrees * cognitive skills to participate (montreal cognitive assessment (moca) \[nasreddine et al 2005\] score 10-30). * subjects may have normal cognition, mci or dementia exclusion criteria: * being younger than 50 or older than 85 years of age * previous stroke * stroke that occurred more than 20 days prior to enrollment * inability to actively extend fingers at least 5 degrees; * fugl-meyer scores of 19 or less; * severe visual neglect or legally blind * severe hearing loss or deafness * receptive aphasia or severe expressive aphasia; * severe spasticity (modified ashworth scale 4/4) * contractures of the upper limb joints * uncontrolled hypertension (\>190/100 mmhg) * severe cognitive impairment determined by montreal cognitive assessment (moca) \[nasreddine et al, 2005\] test of 9 and below; * no chemodenervation or nerve block to upper limb involved during the experimental period (e.g., botulinum toxin injection) * inability to speak english; * a history of violence or drug abuse; * paranoia and psychotic behavior; * inability participate in the neuropsychological pre-study assessment for reliable scores (e.g., cognitive impairment, communication disorders).
the early warning system for the diabetic encephalopathy

Conditions: Diabetes Mellitus Type 2; Mild Cognitive Impairment; Metabolic Syndrome X

Summary: diabetes( mainly type ii diabetes )lead to the central nervous system (cns) function impairment, especially the mild cognitive impairment that increased the risk of progression to dementia.the primary objectives are defined according to a hierarchical design: i) to tailor and apply multi-parametric, functional mri techniques to identify cerebral abnormalities (cerebral biomarkers) in type 2 diabetes mellitus and prodromal diabetes mellitus ; ii) to assess whether these cerebral biomarkers are associated with cognitive decrements;iii) to follow up with the putative prediabetic condition patients to verify whether they can transform into diabetes.

diabetes ( mainly type ii diabetes ) lead to the central nervous system (cns) function impairment, especially the mild cognitive impairment (mci) that increased the risk of progression to dementia. it was regarded that neurodegeneration contributes to the diabetic mci, however, recent research suggested that cns microvascular alterations are the mechanism for early diabetic mci. but there still lacks an early warning system for the cns micro-structure alterations during early diabetes. latest neuroimaging techniques enable the measurement of brain blood flow, local neural activity，and the nuclei deposition of iron to reflect cns micro-structure alterations. but these techniques are complicated and can not fully reflect the alterations with one single technique.we previous observed that 44.4% of diabetic patients demonstrate mci and established the comprehensive protocols of measuring brain blood flow, local neural activity and the nuclei deposition of iron simultaneously based on the multimodal mri technique so as to reflect the microstructure alterations reliably and validly. therefore, we intend to integrate psychological measurement and clinical biochemical examination, and to establish the early warning system for the central nervous system micro-structure alterations during early diabetes based on the multi-modal mri technique. the reliability and validity of this system will be tested in the diabetic rat model. the early warning system will likely assist in screening patients with diabetic microstructure alterations, to perform early intervention so as to prevent or delay the progression from diabetic mci to dementia.

Eligibility criteria:
inclusion criteria: * without dementia * inform consent form * education time more than 6 years * blood glucose matches the group standard exclusion criteria: * pregnant woman * suffer from serious brain disease * magnetic resonance contraindications * lack of compliance * image quality is too poor to deal with

Keywords: diabetes neural and vessel alteration prodromal stage
a multi-national study to identify treatment discontinuation rate in de novo alzheimer's disease patients who have been newly prescribed with donepezil (aricept) in asia (ados)

Conditions: Alzheimer's Disease

Summary: this study is an observational study conducted prospectively under routine clinical setting for 1 year with about 700 patients diagnosed as alzheimer's disease who will be treated by donepezil (aricept) as monotherapy. the subjects will be recruited in the selected institutions of about 8 countries in asia.

participation in this study places no additional visit schedule, which will be determined by the investigator's judgment based on the disease progression of each subject. investigators educate subjects to keep decided visit schedule, and collect the required information for case record from (crf) on the visit.

Eligibility criteria:
inclusion criteria: 1. greater than or equal to 50 years old and less than 90 years old 2. diagnosed as probable ad based on nincds-adrda 3. patients who have been recently prescribed with donepezil (aricept) as monotherapy 4. patients and caregivers who signed the written informed consent from for use of personal and medical information 5. patients with caregivers who can visit the institution together exclusion criteria: 1) patients who have taken memantine or acetylcholinesterase (ache) inhibitor prior to participating in the study

Keywords: alzheimer's disease
sickle cell disease: a retrospective chart review

Conditions: Sickle Cell Anemia

Summary: this study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.


Eligibility criteria:
inclusion criteria: 1. patients with a diagnosis of sickle cell disease (scd) and a confirmed genotype 2. patients ≥ 16 years of age 3. patients with ≥ 6 months of follow-up data available from first scd treatment at the center after they reach 16 years old 4. at least one sf reading during a non-acute phase on or after the first scd treatment at the center after they reach 16 years old exclusion criteria: 1. patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for scd (1) within the six months before the index date or (2) during the patient observation period 2. patients with sickle cell trait other protocol-defined inclusion/exclusion criteria may apply

Keywords: sickle cell anemia
the effect of dexamethasone on the duration and functionality of bupivacaine intercostal nerve blockade

Conditions: Post Minimally Invasive Thorascopic Surgical Pain

Summary: the proposed study is a randomized, double-blinded, non-placebo-controlled evaluation of the effect of the addition of dexamethasone to intraoperative intercostal nerve block bupivicaine solutions on the duration of pain relief and post operative pulmonary function.

our study proposes two groups of 25 patients undergoing similar vats surgery with a single surgeon, dr. r. mckenna, who will receive interoperatively placed intercostal nerve blocks at the same levels. each group will receive intercostals nerve blocks with one of two different solutions: group one will receive intercostal nerve blocks with only 0.46% bupivacaine (19.5 ml of 0.5% bupivacaine + .5 cc saline), group 2 will receive intercostal blocks with 0.46% bupivacaine and dexamethasone(19.5 ml of 0.5% bupivacaine + .5ml .4% dexamethasone). the patients will have pulmonary lung function objectively assessed by portable spirometry and clinical factors both preoperatively and postoperatively. our study objective is to examine and quantify the potentially beneficial effects of intercostal nerve blockade prolongation with dexamethasone on postoperative pulmonary function and postoperative recovery.

Eligibility criteria:
inclusion criteria: * 18 - 80 years old of either gender, scheduled for unilateral vats procedure with dr. mckenna for resection of lung tumor. exclusion criteria: * asa iv and above * intolerance, allergy, or contraindication to use of any medications used in this study * significant coronary artery disease (abnormal stress test, myocardial infarction within the last 3 months) * uncontrolled hypertension (bp \> 140/90) * history of prior ipsilateral thorascopic surgery * cardiac arrhythmias particularly prolonged qt syndrome * drugs known to cause prolonged qt: class ia antiarrhythmics (quinidine, procainamide, dysopyramide), class iii antiarrhythmics (sotalol, dofetalide, ibutalide, amiodarone), haloperidol, thioridazine, arsenic trioxide, hiv protease inhibitors, tricyclic antidepressants * individuals with significant psychological disorders including: schizophrenia, mania, bipolar disorder or psychosis * pregnant or lactating women * morbid obesity (bmi \> 40 kg/m2) and/or weight \> 150 kg * chronic renal failure ( creatinine \> 2.0 mg/dl) * liver failure e.g., active cirrhosis * alcohol or substance abuse within in the past 3 months * uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics, mineralocorticoid use, laxatives) * restrictive lung disease (pulmonary fibrosis, myasthenia gravis) or fev1 or fev less than 70% of predicted value. * type 2 diabetes * neuropathic pain * chronic opioid consumption (\>30mg oxycodone or greater per day) * cahexia from any cause * systemic use of corticosteroids for greater than 2 weeks in the 6 months prior to surgery
effect of progestin-induced withdrawal bleed on ovulation induction cycles with clomiphene citrate

Conditions: Polycystic Ovary Syndrome; Infertility

Summary: women with polycystic ovary syndrome (pcos) can suffer from infertility because they do not produce an egg each month, resulting in irregular periods. as a result, these women often need a medication called clomiphene citrate (clomiphene) to induce ovulation. a traditional 'clomiphene protocol' begins with a short course of progestin treatment to bring on a period (termed a 'withdrawal bleed') before starting the clomiphene medication. newer evidence, however, has suggested that this progestin-induced shedding of the uterine lining (i.e., withdrawal bleed) may decrease the chances of pregnancy. the purpose of our study is to determine whether withdrawal bleeding has an impact on pregnancy rates for patients with pcos undergoing a clomiphene cycle. it is hypothesized that patients who undergo ovulation induction with clomiphene citrate without prior endometrial shedding will have higher clinical pregnancy rates than those who begin with a progestin-induced withdrawal bleed.


Eligibility criteria:
inclusion criteria: * polycystic ovary syndrome (rotterdam 2003 consensus criteria) and a diagnosis of anovulatory infertility * age 18-38 years * at least 1 patent fallopian tube (as demonstrated by hysterosalpingogram, hydrotubation or hysterosonogram within the last year) * normal semen analysis (total motile sperm count \>20million/ml) * normal uterine cavity (as demonstrated by hysterosalpingogram, hydrotubation or hysterosonogram within the last year) * undergoing ovulation-induction with clomiphene citrate without intra-uterine insemination (iui) exclusion criteria: * body mass index (bmi) \ 40 kg/m2 * prior treatment with clomiphene citrate * presence of a hydrosalpinx (as seen on ultrasound, hysterosalpingogram, hydrotubation or hysterosonogram) * those with systemic disease such as diabetes mellitus, uncontrolled thyroid disease, systemic lupus erythematosus and antiphospholipid antibody syndrome * any other cause of infertility other than anovulation

Keywords: polycystic ovary syndrome progestin endometrial shedding ovulation induction cycles clomiphene citrate clinical pregnancy rate
a kinematic analysis of motor planning and movement execution of children with autism spectrum condition

Conditions: Autism; Autism Spectrum Disorder

Summary: autism spectrum condition (asc) is a behavioral syndrome characterized by a severe organizational disorder of thinking and major functions that regulate human adaptation. it is to be considered as a functional disorder, or of executive functions, whose dysfunction is expressed in the difficulty of making voluntary movements, sequentially coordinated with each other according to a purpose, and of initiating an action, planning and monitoring it by inhibiting inappropriate responses such as gesture perseveration. literature studies suggest that, compared to children with typical development (td) and regardless of cognitive status, children with asc have pervasive motor dysfunction that results in universal difficulties in several aspects of motor function, including - (1) fine motricity, (2) some aspects of praxis while performing tasks based on imitation of sequences, (3) simultaneous coordination of both sides of the body during rhythmic tasks of the upper limbs, and́ (4) interpersonal coordination and synchrony. the hypothesis of the study is that by comparing these aspects in 2 groups of children with asc and children with td using a.i. systems, it will be possible to extract objective markers of motor deficits found in autism, facilitating the validation of measurements acquired with clinical scales. the objective of the study is to investigate the characteristics of manual motor planning and performance difficulties in children with asc using kinematic measurements. 30 asc children with medium-high functioning and 30 td children, aged 7 to 13 years, iq \> 80, in the absence of motor deficits due to another clinical condition, will be recruited. the protocol will take place in a single session during which children will be video-recorded performing simple and complex rhythmic upper limb actions with a social partner. the presence of characteristic fine motor behaviors, practice errors, perseverations, movement variability, and interpersonal synchrony will be observed. the study will involve the use of 3 tasks contained in nepsy-ii: finger tapping, visual-motor precision, and imitation of manual motor sequences. the videos will be recorded simultaneously and the different angles will allow hand kinematics to be extracted and analyzed with a.i. algorithms to measure displacement, velocity, acceleration, frequency and any other kinematic parameters highlighted. thus, it is expected to identify objective markers of motor deficits found in children with asc.


Eligibility criteria:
inclusion criteria: * diagnosis of autism * qi ≥ 80. exclusion criteria: * motor deficits due to another clinical condition

Keywords: autism spectrum condition motor planning kinematic analysis children
safety and efficacy of edp1815 in the treatment of patients hospitalized with covid-19 infection

Conditions: Covid19

Summary: evelo will investigate the safety and efficacy of edp1815 in the treatment of patients hospitalized with sars-cov-2 infection

this is a randomized, placebo-controlled clinical study to assess the safety and efficacy of edp1815 in patients hospitalized with covid-19 infection. the study is designed to evaluate the efficacy of edp1815 at reducing time to resolution of symptoms, preventing progression of covid-19 symptoms and preventing covid-related complications (crc)

Eligibility criteria:
key inclusion criteria: 1. hospitalized within the last 36 hours. 2. receiving any form of supplementary oxygen therapy at baseline. 3. confirmed covid-19 viral infection by rtpcr at screening. 4. age: 1. 18-65 years old, or 2. \>65 year-olds can be included after data monitoring committee (dmc) approval key exclusion criteria: 1. contraindications/hypersensitivity to p histicola or any of the capsule excipients 2. patients with chronic hypoxia or underlying significant chronic respiratory disease (such as chronic obstructive pulmonary disease (copd), pulmonary fibrosis, or bronchiectasis). 3. admission to icu at time of screening. 4. mechanically ventilated, on continuous positive airway pressure (cpap), or on non-invasive ventilation at the time of screening. 5. patient is taking a systemic immunosuppressive agent such as, but not limited to, oral steroids, methotrexate, azathioprine, ciclosporin, or tacrolimus, unless these are given as part of covid standard of care treatment. 6. patient has a diagnosed primary immunodeficiency. 7. patient has a diagnosis of hiv/aids 8. patient has pre-existing known chronic kidney disease stage 4 or 5 or requiring renal replacement therapy (i.e. estimated glomerular filtration rate (egfr) \<30ml/min/1.73m2) 9. patient has pre-existing known significant liver disease with alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≥ 5.0 x upper limit of normal (uln) 10. patient has pre-existing known significant gastrointestinal tract disease expected to affect absorption within the small intestine (e.g. short bowel syndrome, inflammatory bowel disease affecting the small intestine, gastroparesis); or prior malabsorptive bariatric surgery that could interfere with gi delivery and transit time. 11. gi signs or symptoms equivalent to ctcae v5.0, gastrointestinal disorders, grade 3 or 4 event. 12. patient has pre-existing known substantially impaired cardiac function or pre-existing clinically significant cardiac diseases, including unstable angina or acute myocardial infarction ≤ 6 weeks prior to screening. 13. currently participating in an interventional clinical trial (observational studies allowed). 14. moribund at time of screening

Keywords: sars-cov-2 corona virus coronavirus corona
evaluation of the effect of narrowband uvb versus methotrexate on serum chitotriosidase level in psoriasis

Conditions: Psoriasis

Summary: the aim of the study is to evaluate the effect of nb-uvb versus mtx on serum chitotriosidase level in psoriatic patients.


Eligibility criteria:
inclusion criteria: * patients with moderate to severe plaque psoriasis of any age and gender. exclusion criteria: * history of psoriasis treatment with systemic and biological agents prior to the study for at least 3 months. * pregnancy and lactation. * infections. * patients with chronic diseases: hepatic disorders, hematologic diseases, chronic renal failure or cancer.
studying gene expression in samples from patients with rhabdoid tumors

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and find biomarkers related to cancer. it may also help doctors find better ways to treat cancer. purpose: this research trial studies gene expression in samples from patients with rhabdoid tumors.

objectives: * to determine if brm is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * to determine if brg1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * to determine if gata1 and/or hdac2 is overexpressed in the same tumors that lack brm expression. * to determine if brm promoter polymorphisms correlate with loss of brm expression in primary rhabdoid tumors. * to determine how brg1 is silenced in primary rhabdoid tumors by sequencing brg1 exons in genomic dna derived from frozen samples. outline: archived tumor tissue samples are analyzed for brm, brg1, gata1, and/or hdac2 expression by immunohistochemistry. brm- and brg1-negative samples are also analyzed.

Eligibility criteria:
disease characteristics: * tumor samples from patients diagnosed with rhabdoid tumors * matched frozen tumor tissue from brg1-negative tumors (preferred) or matched genomic dna from tumors, 100 ng per tumor from brg1-negative tumors * any source of dna from brg1-negative tumors (tumors, blood, etc.) * matched frozen tumor tissue from brm-negative tumors to confirm that brm is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood atypical teratoid/rhabdoid tumor rhabdoid tumor of the kidney